dc.contributor.author | Perez, M.M. | |
dc.contributor.author | Ferrer, M.D. | |
dc.contributor.author | Lazo-Rodriguez, M. | |
dc.contributor.author | Zeralda, A. | |
dc.contributor.author | Banon-Maneus, E. | |
dc.contributor.author | Campistol, J.M. | |
dc.contributor.author | Miller, S. | |
dc.contributor.author | Garg, R. | |
dc.contributor.author | Gold, A. | |
dc.contributor.author | Salcedo, C. | |
dc.contributor.author | Perelló, J. | |
dc.date.accessioned | 2021-02-08T06:37:17Z | |
dc.date.available | 2021-02-08T06:37:17Z | |
dc.identifier.uri | http://hdl.handle.net/11201/155014 | |
dc.description.abstract | [eng] Cardiovascular calcification (CVC) contributes to morbidity and mortality in patients undergoing dialysis. We examined the pharmacodynamic effects of SNF472, a calcification inhibitor, on plasma calcium phosphate crystallization using spectrometric measurements, and its correlations with effects on CVC in rats or humans. Rats (N = 38) injected with vitamin D (days 1-3) to induce CVC were infused with saline or SNF472 (days 1-12). Inhibition of CVC was 50-65% with SNF472 3 mg/kg and ~ 80% with SNF472 10 or 30 mg/kg. SNF472 dose-dependently inhibited calcium phosphate crystallization, which correlated with inhibition of CVC (r = 0.628, P = 0.005). In patients with calciphylaxis (N = 14), infusion of SNF472 (~ 7 mg/kg) during hemodialysis for 12 weeks inhibited calcium phosphate crystallization by nearly 70%. In patients with CVC (N = 274), infusion of SNF472 during hemodialysis for 52 weeks inhibited calcium phosphate crystallization (placebo: 15%; 300 mg: 61%; 600 mg: 75%), which correlated with inhibition of CVC (r = 0.401, P = 0.003). These findings show a direct correlation between inhibition of calcium phosphate crystallization in plasma and inhibition of CVC both in a rat model and in humans, supporting the use of the pharmacodynamic assay in clinical trials as a potentially predictive tool to evaluate the activity of calcification inhibitors. | |
dc.format | application/pdf | |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/s41598-020-74592-x | |
dc.relation.ispartof | Scientific Reports, 2020, vol. 10, num. 17578, p. 1-11 | |
dc.rights | cc-by (c) Perez, M.M. et al., 2020 | |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | |
dc.subject.classification | Ciència | |
dc.subject.other | Science | |
dc.title | A novel assay to measure calcification propensity: from laboratory to humans | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.date.updated | 2021-02-08T06:37:18Z | |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
dc.identifier.doi | https://doi.org/10.1038/s41598-020-74592-x |
The following license files are associated with this item: